In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to Legend Biotech (LEGN – Research Report).

Shares of Legend Biotech Corporation Sponsored ADR (LEGN) have been struggling lately and have lost 9.8% over the past week.

Legend Biotech Corp (NASDAQ:LEGN) received approval for CARVYKTI production in Belgium, expanding its manufacturing capacity ...

Legend Biotech Corporation (NASDAQ:LEGN) Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Ladies and gentlemen, ...

In a report released today, Sami Corwin from William Blair maintained a Hold rating on Legend Biotech (LEGN – Research Report). The ...

Although the revenue and EPS for Legend Biotech (LEGN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with ...

On Tuesday, Legend Biotech Corp (LEGN) stock saw a modest uptick, ending the day at $44.62 which represents a slight increase of $1.01 or 2.32% from the prior close of $43.61. The stock opened at $45 ...

NASDAQ:LEGN opened at $40.03 on Monday. The company has a current ratio of 4.84, a quick ratio of 4.78 and a debt-to-equity ratio of 0.25. Legend Biotech has a 1 year low of $38.60 and a 1 year ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

Below is Validea's guru fundamental report for LEGEND BIOTECH CORP (ADR) (LEGN). Of the 22 guru strategies we follow, LEGN rates highest using our P/B Growth Investor model based on the published ...